Betagrin (batifiban) / Bio-Thera Solutions - LARVOL DELTA

Efficacy and safety of bevifibatide in patients with acute coronary syndrome undergoing percutaneous coronary intervention (BES-PCI): A multicenter, randomized, double-blinded, placebo-controlled, phase III trial. (PubMed, Chin Med J (Engl)) - No abstract available

Clinical • Journal • P3 data • Acute Coronary Syndrome • Cardiovascular

Efficacy and Safety of Bevifibatide Citrate Injection in Patients Undergoing Endovascular Thrombectomy for Acute Ischemic Stroke: A Multi-Center, Randomized, Controlled Trial (ChiCTR) - P4 | N=154 | Not yet recruiting | Sponsor: The First Affiliated Hospital of University of South China; The First Affiliated Hospital of University of South China

New P4 trial • Cardiovascular • Ischemic stroke

Intravenous Bevifibatide in Large Vessel Occlusion Stroke Before Endovascular Thrombectomy: A Randomized, Double-blind, Placebo-controlled Trial (ESOC 2025) - "This trial is currently being prepared and will soon begin."

Clinical • Late-breaking abstract • Cardiovascular • Ischemic stroke

BCAIS-I: A Dose-Response Controlled Trial of Bevifibatide for Acute Ischemic Stroke (clinicaltrials.gov) - P2 | N=40 | Recruiting | Sponsor: Zhujiang Hospital | Not yet recruiting ➔ Recruiting

Enrollment open • Cardiovascular • CNS Disorders • Ischemic stroke

Efficacy and Safety of Bevifibatide Citrate Injection in Patients with Acute Ischemic Stroke without Large or Medium-Sized Vessel Occlusion: A Single-Center, Randomized, Double-Blind, Dose-Response Controlled Clinical Trial (ChiCTR) - P=N/A | N=40 | Not yet recruiting | Sponsor: Zhujiang Hospital of Southern Medical University; Zhujiang Hospital of Southern Medical University

New trial • Cardiovascular • Ischemic stroke